A securities class action lawsuit has been filed against Corcept and certain officers, alleging violations of federal securities laws. The suit seeks damages on behalf of investors who bought or acquired Corcept securities between Oct. 31, 2024 and Dec. 30, 2025. The complaint alleges Corcept overstated the strength of clinical trial support for relacorilant in connection with its FDA new drug application. It also alleges the company gave an inaccurate impression of regulatory prospects despite repeated FDA concerns about the adequacy of the clinical evidence.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603171400PRIMZONEFULLFEED9673668) on March 17, 2026, and is solely responsible for the information contained therein.